A systematic review of health economic evaluations of vaccines in Brazil.

Ana Marli Christovam Sartori, Luciana Martins Rozman, Tassia Cristina Decimoni, Roseli Leandro, Hillegonda Maria Dutilh Novaes, Patrícia Coelho de Soárez
Author Information
  1. Ana Marli Christovam Sartori: a Departamento de Moléstias Infecciosas e Parasitárias , Faculdade de Medicina, Universidade de São Paulo , São Paulo , Brazil.
  2. Luciana Martins Rozman: b Departamento de Medicina Preventiva , Faculdade de Medicina, Universidade de São Paulo , São Paulo , Brazil.
  3. Tassia Cristina Decimoni: b Departamento de Medicina Preventiva , Faculdade de Medicina, Universidade de São Paulo , São Paulo , Brazil.
  4. Roseli Leandro: b Departamento de Medicina Preventiva , Faculdade de Medicina, Universidade de São Paulo , São Paulo , Brazil.
  5. Hillegonda Maria Dutilh Novaes: b Departamento de Medicina Preventiva , Faculdade de Medicina, Universidade de São Paulo , São Paulo , Brazil.
  6. Patrícia Coelho de Soárez: b Departamento de Medicina Preventiva , Faculdade de Medicina, Universidade de São Paulo , São Paulo , Brazil.

Abstract

BACKGROUND: In Brazil, since 2005, the Ministry of Health requires Health Economic Evaluation (HEE) of vaccines for introduction into the National Immunization Program.
OBJECTIVES: To describe and analyze the full HEE on vaccines conducted in Brazil from 1980 to 2013.
METHODS: Systematic review of the literature. We searched multiple databases. Two researchers independently selected the studies and extracted the data. The methodological quality of individual studies was evaluated using CHEERS items.
RESULTS: Twenty studies were reviewed. The most evaluated vaccines were pneumococcal (25%) and HPV (15%). The most used types of HEE were cost-effectiveness analysis (45%) and cost-utility analysis (20%). The research question and compared strategies were stated in all 20 studies and the target population was clear in 95%. Nevertheless, many studies did not inform the perspective of analysis or data sources.
CONCLUSIONS: HEE of vaccines in Brazil has increased since 2008. However, the studies still have methodological deficiencies.

Keywords

References

  1. Pharmacoeconomics. 1999 Nov;16(5 Pt 2):563-76 [PMID: 10662481]
  2. Health Aff (Millwood). 2000 Mar-Apr;19(2):92-109 [PMID: 10718025]
  3. Proc AMIA Symp. 2000;:625-9 [PMID: 11079959]
  4. Commun Dis Public Health. 2002 Sep;5(3):220-5 [PMID: 12434692]
  5. Br J Cancer. 2003 Oct 20;89(8):1405-8 [PMID: 14562007]
  6. J Hosp Infect. 2004 Mar;56(3):228-31 [PMID: 15003672]
  7. Schizophr Res. 2004 Dec 1;71(2-3):445-62 [PMID: 15474916]
  8. Rev Saude Publica. 2005 Feb;39(1):122-8 [PMID: 15654469]
  9. MMWR Morb Mortal Wkly Rep. 2005 Sep 16;54(36):893-7 [PMID: 16163262]
  10. Pharmacoeconomics. 2008;26(1):17-32 [PMID: 18088156]
  11. Clin Ther. 2008 Feb;30(2):341-57 [PMID: 18343273]
  12. Rev Panam Salud Publica. 2008 Apr;23(4):221-30 [PMID: 18505602]
  13. Epidemiol Infect. 2009 Feb;137(2):241-9 [PMID: 18631422]
  14. Vaccine. 2008 Nov 18;26(49):6281-91 [PMID: 18674582]
  15. Lancet Infect Dis. 2008 Nov;8(11):727-33 [PMID: 18992409]
  16. J Health Popul Nutr. 2008 Dec;26(4):388-96 [PMID: 19069617]
  17. Vaccine. 2009 Jul 23;27(34):4694-703 [PMID: 19520197]
  18. Vaccine. 2010 Mar 8;28(11):2356-9 [PMID: 19567247]
  19. Rev Panam Salud Publica. 2009 Dec;26(6):518-28 [PMID: 20107706]
  20. Pharmacoeconomics. 2010;28(4):295-306 [PMID: 20222753]
  21. Breast Cancer Res Treat. 2010 Jun;121(2):273-9 [PMID: 20352486]
  22. Value Health. 2010 Dec;13(8):1028-37 [PMID: 20667054]
  23. J Epidemiol Community Health. 2012 Mar;66(3):210-7 [PMID: 20884668]
  24. Am J Clin Oncol. 2011 Oct;34(5):524-8 [PMID: 21441858]
  25. Med Decis Making. 2012 Mar-Apr;32(2):237-45 [PMID: 21490308]
  26. Pharmacoeconomics. 2011 Aug;29(8):641-52 [PMID: 21604821]
  27. Cien Saude Colet. 2011 Jul;16(7):3103-10 [PMID: 21808898]
  28. Value Health. 2011 Jul-Aug;14(5 Suppl 1):S108-14 [PMID: 21839880]
  29. Hum Vaccin. 2011 Oct;7(10):1037-47 [PMID: 21941088]
  30. Lancet Infect Dis. 2012 Apr;12(4):300-6 [PMID: 22071248]
  31. Value Health. 2011 Dec;14(8):1019-27 [PMID: 22152170]
  32. J Clin Oncol. 2012 Apr 20;30(12):1316-20 [PMID: 22430267]
  33. Vaccine. 2012 Jul 6;30(32):4866-71 [PMID: 22652405]
  34. Clin Microbiol Infect. 2012 Oct;18 Suppl 5:70-6 [PMID: 22882176]
  35. BMC Infect Dis. 2012 Oct 09;12:250 [PMID: 23046886]
  36. Vaccine. 2012 Dec 14;30(52):7489-97 [PMID: 23107593]
  37. Hum Vaccin Immunother. 2013 May;9(5):1139-41 [PMID: 23364247]
  38. Vaccine. 2013 Mar 25;31(13):1656-65 [PMID: 23370153]
  39. Value Health. 2013 Mar-Apr;16(2):231-50 [PMID: 23538175]
  40. Vaccine. 2013 Jul 2;31 Suppl 3:C12-8 [PMID: 23777685]
  41. Vaccine. 2013 Aug 20;31(37):3957-61 [PMID: 23791696]
  42. PLoS One. 2013 Jul 08;8(7):e69462 [PMID: 23861972]
  43. Rev Assoc Med Bras (1992). 2013 Sep-Oct;59(5):442-51 [PMID: 24041909]
  44. Pharmacoeconomics. 2014 Jun;32(6):525-31 [PMID: 24791735]
  45. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12313-9 [PMID: 25136129]
  46. Cad Saude Publica. 2013 Nov;29 Suppl 1:S59-72 [PMID: 25402251]
  47. Rev Saude Publica. 2015;49:8 [PMID: 25741645]
  48. Bull World Health Organ. 2015 Feb 1;93(2):118-24 [PMID: 25883405]
  49. Vaccine. 2015 May 7;33 Suppl 1:A135-42 [PMID: 25919154]
  50. Vaccine. 2015 May 7;33 Suppl 1:A21-7 [PMID: 25919164]
  51. Vaccine. 2015 May 7;33 Suppl 1:A28-33 [PMID: 25919170]
  52. Vaccine. 2015 Nov 17;33(46):6164-72 [PMID: 26435189]
  53. Pharmacoeconomics. 2016 Mar;34(3):227-44 [PMID: 26477039]
  54. Appl Health Econ Health Policy. 2016 Jun;14(3):245-52 [PMID: 26832145]
  55. Hum Vaccin Immunother. 2016 May 3;12(5):1257-64 [PMID: 26890128]
  56. Vaccine. 2016 Mar 18;34(13):1531-1539 [PMID: 26899375]
  57. Value Health. 2014 Nov;17(7):A438 [PMID: 27201167]
  58. Bull World Health Organ. 2016 Dec 1;94(12):925-930 [PMID: 27994285]
  59. Value Health Reg Issues. 2013 Dec;2(3):405-412 [PMID: 29702778]
  60. Rev Soc Bras Med Trop. 1995 Oct-Dec;28(4):393-403 [PMID: 8668841]

MeSH Term

Brazil
Communicable Diseases
Cost-Benefit Analysis
Humans
Immunization Programs
Vaccines

Chemicals

Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccinesstudiesBrazilHEEanalysisreviewsinceHealthdatamethodologicalevaluatedsystematiceconomicBACKGROUND:2005MinistryrequiresEconomicEvaluationintroductionNationalImmunizationProgramOBJECTIVES:describeanalyzefullconducted19802013METHODS:SystematicliteraturesearchedmultipledatabasesTworesearchersindependentlyselectedextractedqualityindividualusingCHEERSitemsRESULTS:Twentyreviewedpneumococcal25%HPV15%usedtypescost-effectiveness45%cost-utility20%researchquestioncomparedstrategiesstated20targetpopulationclear95%NeverthelessmanyinformperspectivesourcesCONCLUSIONS:increased2008Howeverstilldeficiencieshealthevaluationscosteffectivenesscost-benefitevaluationimmunizationprograms

Similar Articles

Cited By (3)